Bioengineering & Translational Medicine Conference

该奖项为第二届生物工程和转化医学大会提供支持，作为美国化学工程师学会年会的会前会议。它将于2017年10月27日至28日在明尼苏达州明尼阿波利斯举行。组委会由学术界和业界代表组成，总体目标是将医生、科学家和工程师聚集在一起，讨论如何将适当的生物工程发现转化为可用于患者治疗的药物和医疗器械。除了侧重于翻译过程的主题外，还将组织5个科学主题的会议，包括风险投资、知识产权、监管问题和商业实践。这些资金将用于部分资助年轻科学家和工程师参加会议的旅费，以便他们有机会与其他大学的学者、医生和行业代表建立联系。会议的科学目标是推动将生物工程转化为医疗设备和系统，这将对健康结果产生积极影响，并有可能降低医疗成本。生物工程与转化医学是一个独特的领域，集生物制药、基因和药物输送、免疫工程、生物制造、干细胞和再生医学的前沿进展于一身。最终目标是将台式科学和工程发现转化为实际的临床实践，并改善患者的结果。本次会议将讨论与这些主题相关的科学和工程领域的最新进展，以及将它们转移到临床翻译所需的步骤。此外，会议将讨论与非科学方面的翻译有关的问题，包括风险投资、法规和知识产权。由于这是一次单轨会议，不同的与会者群体将有机会扩大他们对生物工程广泛范围的理解，并提高他们与翻译过程本身相关的知识基础。该奖项将为受邀演讲者提供部分旅行支持，并为学生和博士后研究员提供部分旅行补助和注册豁免，使他们能够参加会议并与学术界和工业界的该领域领导人建立网络。

This award provides support to the 2nd Bioengineering & Translational Medicine Conference as a pre-conference to the American Institute of Chemical Engineers annual meeting. It will be held October 27-28, 2017, in Minneapolis, MN. The organizing committee consists of academic and industry representatives, and the overall goal is to bring together physicians, scientists, and engineers to discuss ways of turning appropriate biological engineering discoveries into drugs and medical devices that can be used in the treatment of patients. Sessions will be organized in 5 scientific themes in addition to a theme focused on the process of translation, including venture capital, intellectual property, regulatory issues, and business practices. These funds will be used to partially fund travel grants for young scientists and engineers to attend the conference so that they can have the opportunity to network with academics from other universities, physicians, and industry representatives. The scientific objective of the meeting seeks to advance the translation of bioengineering into medical devices and systems, which will subsequently have a positive impact on health outcomes and, potentially, reducing health care costs.Bioengineering & translational medicine is a distinct field at the intersection of cutting edge advances in the translation of biopharmaceuticals, gene and drug delivery, immunoengineering, biomanufacturing, stem cells and regenerative medicine. The ultimate goal is to move benchtop scientific and engineering discoveries to actual clinical practice and improve patient outcomes. This meeting will discuss the latest advances in the science and engineering related to these themes as well as the steps required to move them to clinical translation. In addition, the meeting will address issues related to translation on the non-science side, including venture capital, regulation, and intellectual property. As this is a single track conference, the diverse group of attendees will have an opportunity to broaden their understanding of a broad scope of bioengineering as well as improve their foundation of knowledge related to the translation process itself. The award will provide partial travel support to invited speakers as well as partial travel grants and registration waivers to students and post-doctoral fellows to allow them to attend the conference and network with leaders in the field from both academia and industry.